转移性去势抵抗性前列腺癌的转录组分型用于精准治疗:一项基于数据的分析
该研究分析了231例转移性去势抵抗性前列腺癌(mCRPC)的转录组,识别出四种生物学亚型(基底型、同源重组修复型、神经内分泌型和管腔型),并构建随机森林模型。结果显示管腔型AR表达更高,HRR和神经内分泌型HRR通路基因下调可能对PARP抑制剂耐药,HRR型免疫细胞浸润更多,基底型TMPRSS2-ERG融合频率更高。结论认为转录组分型对个体化治疗有信息价值,其预测能力需进一步探索。
要点
- mCRPC可分为基底型、HRR型、神经内分泌型和管腔型四种转录组亚型。
- 管腔型AR表达和拷贝数改变高于其他亚型。
- HRR和NE亚型HRR通路基因下调,可能对PARP抑制剂耐药。
核心结论
- 结果表明,根据转录组对mCRPC进行分层可为mCRPC的个体化治疗提供信息。
- mCRPC转录组分型的预测能力需在未来进一步探索。
研究设计与样本
- 基于数据的分析,分析了231例mCRPC的转录组,识别出四种生物学亚型(基底型、HRR、神经内分泌和管腔型)。
- 使用randomForest包构建随机森林模型,并用环形图可视化各亚型中的TMPRSS2-ERG融合。
主要发现
- 管腔型mCRPC与其他亚型相比具有更高的雄激素受体(AR)表达和拷贝数改变。
- 除HRR和NE亚型外,大多数亚型中HRR通路基因相对下调,无论遗传改变如何,提示HRR和NE型mCRPC对PARP抑制剂治疗可能存在耐药。
- HRR亚型具有相对更多的免疫细胞浸润和更高的免疫检查点表达,提示应在该特定亚型中评估免疫治疗的疗效。
- TMPRSS2-ERG融合是所有mCRPC中最常见的基因融合,基底型该融合频率高于其他亚型。
临床怎么用
- 原文未据此给出推荐。
局限性
- mCRPC转录组分型的预测能力需在未来进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Men with metastatic prostate cancer who are treated with androgen deprivation therapy (ADT) typically develop therapeutic resistance eventually and have a dismal outcome. Moreover, the limited survival benefit observed in only a proportion of patients receiving novel therapeutics including immune checkpoint blockade and PARP inhibitors suggests the biological heterogeneity of mCRPCs. METHODS: To understand the heterogeneity of mCRPC, we analyzed the transcriptome of 231 mCRPCs and identified four disparate biological subtypes (Basal, Homologous Recombination Repair (HRR), Neuroendocrine and Luminal). The package "randomForest" was used to construct a Random Forest model. Circular plots were used for visualization of TMPRSS2-ERG fusion in each subtype. RESULTS: The Luminal subtype of mCRPCs has higher Androgen Receptor (AR) expression and copy number alterations as compared with the other subtypes. Genes in HRR pathway are relatively downregulated in most subtypes regardless of the genetic alterations, except for the HRR and NE subtypes, suggesting potential resistance of the HRR and NE mCRPCs to PARP inhibitor treatment. The HRR subtype has relatively more immune cell infiltration and higher expression of immune checkpoints, highlighting that the efficacy of immunotherapy should be evaluated in this particular subtype. TMPRSS2-ERG fusion is the most frequent gene fusion in all mCRPCs, and the Basal subtype has a higher frequency of this fusion than the other subtypes. CONCLUSIONS: Our results reveal that the stratification of mCRPC according to transcriptome is informative of personalized therapeutics in the treatment of mCRPCs. The predictive capacity of the transcriptome subtyping of mCRPC warrants further exploration in the future.
引用
- Liang Y, Rong E, Qian J, et al. Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis. Prostate Cancer Prostatic Dis. 2022. PMID: 35079116. doi:10.1038/s41391-022-00495-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。